Plasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemic.

Convalescent plasma therapy holds promise as a transient treatment for COVID-19. Yet, blood products are important sources of HIV infection in low- and middle-income nations. Great care must be taken to prevent plasma therapy from fueling HIV epidemics in the developing world.